Trial of a long-acting somatostatin analogue for autosomal dominant polycystic kidney disease

被引:0
|
作者
Susan J. Allison
机构
关键词
D O I
10.1038/nrneph.2013.154
中图分类号
学科分类号
摘要
引用
收藏
页码:553 / 553
相关论文
共 50 条
  • [1] Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease
    Hogan, Marie C.
    Masyuk, Tetyana V.
    Page, Linda J.
    Kubly, Vickie J.
    Bergstralh, Eric J.
    Li, Xujian
    Kim, Bohyun
    King, Bernard F.
    Glockner, James
    Holmes, David R., III
    Rossetti, Sandro
    Harris, Peter C.
    LaRusso, Nicholas F.
    Torres, Vicente E.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 21 (06): : 1052 - 1061
  • [2] Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis
    Griffiths, Joshua
    Mills, Mark T.
    Ong, Albert C. M.
    BMJ OPEN, 2020, 10 (01):
  • [3] Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease
    Ruggenenti, P
    Remuzzi, A
    Ondei, P
    Fasolini, G
    Antiga, L
    Ene-Iordache, B
    Remuzzi, G
    Epstein, FH
    KIDNEY INTERNATIONAL, 2005, 68 (01) : 206 - 216
  • [4] Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan
    Higashihara, Eiji
    Nutahara, Kikuo
    Okegawa, Takatsugu
    Tanbo, Mitsuhiro
    Mori, Hideaki
    Miyazaki, Isao
    Nitatori, Toshiaki
    Kobayashi, Kuninori
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2015, 19 (04) : 746 - 752
  • [5] Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan
    Eiji Higashihara
    Kikuo Nutahara
    Takatsugu Okegawa
    Mitsuhiro Tanbo
    Hideaki Mori
    Isao Miyazaki
    Toshiaki Nitatori
    Kuninori Kobayashi
    Clinical and Experimental Nephrology, 2015, 19 : 746 - 752
  • [6] Somatostatin in renal physiology and autosomal dominant polycystic kidney disease
    Messchendorp, A. Lianne
    Casteleijn, Niek F.
    Meijer, Esther
    Gansevoort, Ron T.
    Drenth, Joost P.
    de Fijter, Johan W.
    Peters, Dorien J. M.
    Visser, Folkert W.
    Wetzels, Jack F.
    Zietse, Robert
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 (08) : 1306 - 1316
  • [7] Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement A Randomized Clinical Trial
    Hogan, Marie C.
    Chamberlin, Julie A.
    Vaughan, Lisa E.
    Waits, Angela L.
    Banks, Carly
    Leistikow, Kathleen
    Oftsie, Troy
    Madsen, Chuck
    Edwards, Marie
    Glockner, James
    Kremers, Walter K.
    Harris, Peter C.
    LaRusso, Nicholas F.
    Torres, Vicente E.
    Masyuk, Tatyana V.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (09): : 1267 - 1278
  • [8] Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial
    Caroli, Anna
    Perico, Norberto
    Perna, Annalisa
    Antiga, Luca
    Brambilla, Paolo
    Pisani, Antonio
    Visciano, Bianca
    Imbriaco, Massimo
    Messa, Piergiorgio
    Cerutti, Roberta
    Dugo, Mauro
    Cancian, Luca
    Buongiorno, Erasmo
    De Pascalis, Antonio
    Gaspari, Flavio
    Carrara, Fabiola
    Rubis, Nadia
    Prandini, Silvia
    Remuzzi, Andrea
    Remuzzi, Giuseppe
    Ruggenenti, Piero
    LANCET, 2013, 382 (9903): : 1485 - 1495
  • [9] Concurrent Targeting of Vasopressin Receptor 2 and Somatostatin Receptors in Autosomal Dominant Polycystic Kidney Disease: A Promising Approach for Autosomal Dominant Polycystic Kidney Disease Treatment?
    Hogan, Marie C.
    Masyuk, Tatyana V.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (02): : 154 - 156
  • [10] Autosomal dominant polycystic kidney disease
    Simms, Roslyn J.
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 352